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Abstract 
 
Background  
One of the major challenges limiting  development of gene therapy is absence of efficient and 
safe gene carriers. Among the non-viral gene delivery methods, lipofection is considered as 
one of the most promising. In this study a set of cationic polyprenyl derivatives 
(trimethylpolyprenylammonium iodides – PTAI) with different lengths of polyprenyl chains 
(from 7, 8 and 11 to 15 isoprene units) was suggested as a component of efficient DNA 
vehicles.  
Methods 
Optimization studies were conducted for PTAI in combination with co-lipid DOPE 
(dioleoylphosphatidylethanolamine) on DU145 human prostate cancer cells using: size and 
zeta potential measurements, confocal microscopy, fluorescein diacetate/ethidium bromide 
test, cell counting, time-lapse monitoring of cell movement, gap junctional intracellular 
coupling analysis, antimicrobial activity assay, red blood cell hemolysis test. 
Results 
The results show that the lipofecting activity of PTAI allows effective transfection of plasmid 
DNA complexes in negatively charged lipoplexes of 200 - 500 nm size into cells without 
significant side effects on cell physiology (viability, proliferation, morphology, migration and 
gap junctional intercellular coupling – GJIC). Moreover, PTAI-based vehicles exhibit a 
potent bactericidal activity against Staphylococcus aureus and Escherichia coli. The 
developed anionic lipoplexes are safe towards human red blood cell membranes which are 
not disrupted in their presence.  
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Conclusions 
The developed carriers constitute a group of promising lipofecting agents of a new type and 
can be utilized as effective lipofecting agents in vitro and are a promising basis for in vivo 
applications. 
 
Keywords 
 
Gene – delivery, gene therapy, gene – transfer, plasmid – gene delivery, plasmid – 
transfection, vector – non-viral, transfection, enhanced green fluorescent protein (eGFP). 
 
Introduction 
Progress in understanding the pathogenesis of many disorders and enormous 
methodological development that has been made in the field of nucleic acid transfer 
technology has opened perspectives for new applications of DNA and RNA delivery 
techniques and their introduction into laboratory and clinical practice. In fact, nucleic acids 
are nowadays regarded as drugs against a constantly increasing number of genetic and 
acquired diseases. These include hemophilia, autosomal dominant disorders, immune 
deficiency, chronic inflammation and intractable pain, as well as HIV, cystic fibrosis, 
artherosclerosis, rheumatoid arthritis and cancer [1]. The promising and continuously 
growing potential of gene therapy for the treatment of diseases currently considered as 
incurable, prompts research for effective vectors that could be safely applied in vivo.  
Whereas the most effective gene delivery strategies are based on viral vectors, their 
application in clinics meets a number of substantial obstacles, i.e. a limited payload capacity, 
mutagenic, oncogenic and auto-immunogenic side effects, and expensive large-scale 
production [2]. Non-viral vehicles represent a promising alternative because they are safe and 
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relatively cheap in large-scale production. Among the gene transfer strategies employing non-
viral vectors, lipofection is considered as one of the most promising options. Lipid-based 
carriers are appreciated for their versatility, low immunogenicity, simplicity of application 
and easy modification to meet case-specific requirements [3]. The lipofection strategy is 
mostly based on cationic lipids which can spontaneously interact with negatively charged 
nucleic acids to form lipoplexes (complexes of lipids and DNA). Their non-specific 
interaction with cell surface proteins and sugars on the plasma membrane stimulates the 
endocytic pathway leading to formation of endosomal vesicles. Mixtures of cationic and 
neutral lipids (also designated as helper or co-lipids), for instance DOPE 
(dioleoylphosphatidylethanolamine), change the properties of lipoplexes facilitating 
endosomal escape of nucleic acids [4],[5]. DOPE promotes formation of more fusogenic 
inverted hexagonal structures, compared to other helper lipids that form more stable laminar 
structures e.g. DOPC [6]. 
Due to their potential as vectors for genetic drug delivery, intensive research has been 
recently carried out to elaborate an optimal lipid carrier. Despite the fact that numerous 
cationic and helper lipids have been synthesized, many of them being the subjects of patent 
applications [7], none of the so far developed lipofecting formulas appear ideal. This may 
result from the fact that the lipofection efficiency depends not only on the composition of 
lipids and co-lipids, but also on the properties of target cells and the conditions of lipofection 
(e.g. in vitro vs. in vivo). Furthermore, the multitude of pathways and mechanisms implicated 
in the process of lipofection accounts for the complexity of the structure-safety-efficiency 
relationships [8]–[10]. Conflicting reports on the effect of vectors and lipoplex properties on 
transfection efficiency additionally hinder the application of new lipids and co-lipids in gene 
delivery [7],[11]–[16]. Therefore, trials on the improvement of the lipofection strategy are 
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still largely based on empirical approaches towards the formulation of optimal lipids, 
especially in the case of new and distinct classes of lipofecting compounds.  
Polyisoprenoids are lipid components of the cellular glycosylation machinery in 
prokaryotes (polyprenol) and eukaryotes (dolichol) and are biosynthetically interconnected 
with other crucial elements of cellular metabolism (e.g. ubiquinone, cholesterol, prenylated 
proteins). Moreover, polyprenols and dolichols are known to increase the fluidity and 
permeability of lipid membranes [5,6 and references therein], and these physico-chemical 
properties stimulated us to synthesize the cationic derivatives of polyprenyl alcohols. Such 
forms of polyprenols or dolichols are most probably absent in living organisms, but can be 
synthesized chemically from isoprenoid alcohols accumulated in the cells. Previously, we 
have described preliminary yet encouraging data on the lipofecting activity of polyprenyl 
derivatives [19], which prompted further chemical approaches to synthesize analogues of a 
similar structure [20]. 
The aim of the present study was to estimate the lipofecting potential and cellular effects of 
the set of cationic polyprenyl derivatives (trimethylpolyprenylammonium iodides – PTAI) 
with different lengths of polyprenyl chains (from 7, 8 and 11 to 15 isoprene units). 
Comprehensive analyses of their properties also enabled the optimization of the lipofecting 
mixture and to define the factors crucial for lipofecting efficiency, cytotoxic and cytostatic 
effect of PTAI.  
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Materials and methods 
 
PTAI chemical synthesis and purification  
Trimethylpolyprenylammonium iodides (PTAI, Fig. 1) differing in the numbers of isoprenoid 
residues (n = 7, 8, 11, 15) were prepared from naturally occurring polyprenols according to 
Madeja et al. 2007 [19], with modifications. All polyprenols for the synthesis of cationic 
derivatives were from the Collection of Polyprenols, Institute of Biochemistry and 
Biophysics PAS, Warsaw. The relevant preparation procedures were described in a patent 
application (PL 2012, B1 211824). All products were stable as demonstrated by thin-layer 
chromatography on silica gel plates (Merck), which showed single spots in 
chloroform/methanol/water (65 : 25 : 4, ; Rf = 0.66);  in n-butanol/acetic acid/water (66 : 17 : 
17; Rf = 0.23); in n-propanol/ammonia/water (8 : 1 : 1; Rf = 0.10) and in ethyl 
acetate/methanol/acetic acid (75 : 20 : 5; Rf = 0.03). No symptoms of decomposition were 
noticed after the TLC test for any of the compounds after one year of storage in a dry state in 
the argon atmosphere at -80ºC.  
 
Cell cultures  
Human prostate cancer DU145 cells were cultured in DMEM F12 HAM medium (Sigma-
Aldrich, St. Louis, USA), supplemented with 10% heat-inactivated fetal calf serum (FCS; 
Gibco Lab., New  York, USA), 100 IU/ml penicillin, 10/µg/ml neomycin and 10 µg/ml 
streptomycin (Polfa, Tarchomin, Poland) in a humidified atmosphere with 5% CO2 at 37°C. 
Escherichia coli and Staphylococcus aureus were cultured on tryptic soy agar (TSA; Sigma-
Aldrich, St. Louis, USA) – E. coli and LB (Bioshop, Burlington, Canada) agar plates – S. 
aureus, respectively. 
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Preparation of lipofecting mixtures and transfection procedure  
PTAIs (PTAI-7, -8, -11,  or -15) and helper lipid L-α-phosphatidylethanolamine dioleyl 
(DOPE, Sigma-Aldrich, St. Louis, USA) were dissolved in 99% ethanol to achieve final 
concentrations of 10 mg/ml and 3.2 mg/ml, respectively. Next, they were diluted in serum-
free DMEM F12 HAM medium at the indicated PTAI/DOPE ratio and vortexed extensively 
(half of the maximal speed of Grant-bio PV-1 vortex mixer (Grant Instruments, Cambridge, 
UK) for 3 min to obtain a PTAI+DOPE solution (ethanol content around 47%). The plasmid 
pEGFP-C1 encoding “enhanced green fluorescent protein GFP” (kindly supplied by 
Professor A. F. Sikorski, University of Wrocław, Poland) was dissolved in serum-free 
DMEM F12 HAM to the final concentration of 0.08 µg/µl. Equal volumes of the 
PTAI+DOPE solution (the final concentration indicated in the text) and plasmid DNA were 
gently mixed by pipetting (ethanol content 0.2 – 6% depending on the applied PTAI), 
incubated for 30 min at room temperature to obtain lipoplexes and diluted in serum-free 
DMEM F12 HAM medium (1:4; ethanol content 0.1 – 1.5 %). 
DU145 cells were seeded into the wells of a 24-well plate at a density of 8×10
4
 cell/well 
and cultivated for 24 h in DMEM F12 HAM medium with 10% FCS without antibiotics (to 
reach 70–80% confluence). Next, the medium was aspirated and replaced with 200 µl of 
serum-free DMEM F12 HAM medium and 200 µl of the lipoplex suspension. After 5 h of 
incubation at 37°C in 5% CO2, 400 µl of DMEM F12 HAM medium supplemented with 20% 
of FBS and antibiotics was added to the transfection medium. The Lipofectamine 2000 
Reagent (Invitrogen–Life Technologies, Carlsbad, USA) was used as a positive control. For 
cell transfection, diluted pEGFP-C1 plasmid was combined with diluted Lipofectamine 2000 
(1 µl of Lipofectamine 2000: 2 µg of plasmid) and incubated for 30 min at RT. Then, the 
diluted complexes were used for the transfection procedure as described above. 
8 
 
This article is protected by copyright. All rights reserved. 
The transfection efficiency was calculated after 24 h of cell incubation with lipoplexes. 
Cells were washed with PBS, incubated in the presence of Hoechst 33342 (1 µg/ml in PBS; 
Sigma-Aldrich, St. Louis, USA) for 10 min, washed again with PBS and submerged in 
DMEM F12 HAM medium with 10% FBS. The percentage of transfected cells was 
calculated under fluorescent Leica DM IRE2 microscope (Leica Microsystems GmbH, 
Wetzlar,  Germany) equipped with Leica DC350 FX digital camera according to the 
following formula: Le= (NGFP/NHoe) × 100% (where NGFP -Number of cells expressing GFP; 
NHoe - Number of cells stained with Hoechst 33342).   
 
Confocal microscopy analysis  
The PTAI-7+DOPE-based lipofecting mixture was prepared as described above and used to 
make a lipoplex mixture with Cy-3-labeled plasmid DNA (2.7 kb, Label IT Plasmid Delivery 
Control, Mirus Bio LLC, Madison, USA). After transfection in standard conditions, DU145 
cells were fixed with 3.7%-formaldehyde, permeabilized with 0.1% Triton X-100 and 
counterstained with Hoechst 33342. Cells were visualized with Leica TCS SP5 II scanning 
confocal microscope and data was analysed with Leica Application Suite Advanced 
Fluorescence (LAS AF) software. 
 
Gel retardation assay 
Lipoplexes were prepared as described above and mixed with the loading dye solution to 
achieve a final concentration of pEGFP-C1 plasmid 0.04 µg/µl, and incubated for 30 min at 
RT. Then, they were loaded onto 0.8% agarose gel (TAE buffer) stained with SimplySafe dye 
(EURx, Gdańsk, Poland). Perfect Plus 1 kb DNA Ladder (EURx) was used as an internal 
control. Electrophoresis was carried out under a constant electric field (65 V, 60 min) at RT. 
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Size and zeta potential measurements  
Vectors and lipoplexes were prepared as described above. Lipoplexes were prepared in 
DMEM F12 HAM medium. Malvern Nano ZS light-scattering apparatus (Malvern 
Instrument Ltd., Worcestershire, UK) was used for dynamic light scattering (DLS) and zeta 
potential measurements. The samples were illuminated with a 633 nm laser, and the 
intensities of scattered light at the angle of 173° were measured using an avalanche 
photodiode. A diameter (Intensity PSD mode) and dispersity (PDI) were automatically 
calculated using the software provided by Malvern. The zeta potential was measured using 
the technique of laser Doppler velocimetry (LDV).  
 
Cell viability and proliferation assays  
To determine the effect of PTAI-7/8/11/15 + DOPE lipoplexes on cell viability, DU145 cells 
were incubated with optimal concentrations of lipoplexes for transfection. After indicated 
time intervals, cells were harvested and the number of viable cells was determined by the 
fluorescein diacetate/ethidium bromide test [21]. At that point the number of cells was also 
determined for proliferation analysis. 
 
Cell motility assay  
Motility of DU145 cells was estimated 24 h after transfection by time-lapse monitoring of 
their trajectories. Tracks of individual cells were determined from the series of changes in 
cell centroid positions (8 h with 5 minute intervals), pooled and analysed as previously 
described [22],[23].  
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Gap junctional intracellular coupling (GJIC) analyses  
GJIC intensity was measured by a fluorescent dye transfer assay as previously described [24] 
with some modifications. Briefly, donor DU145 cells labelled with calcein and DiI (both 
from Invitrogen-Life technologies, Carlsbad, USA) were plated (at a ratio of 1:50) onto 
monolayers of DU145 acceptor cells, 24 h after transfection with PTAI-based lipoplexes. The 
dynamics of calcein transfer from the donor to acceptor cells was visualized using Leica 
DMI6000B-AF7000 microscope and the percent of donor cells capable of coupling with at 
least one acceptor cell within 1 h after seeding was calculated as the coupling index – Ci. 
 
Antimicrobial activity assay  
The antimicrobial activity of PTAI-7/8/11/15+DOPE vectors and lipoplexes was analysed by 
colony reduction assay. E. coli (strain ATCC 33694) and S. aureus (strain ATCC 29213) 
were suspended in RPMI-1640 medium (PAA; GE Healthcare Life Sciences, Little Chalfont, 
UK) with 10% HBSS (PAA; 3.6×10
6
 and 3.6×10
5
 cells/ml, respectively) and mixed in 1:1 
volume ratio with samples of DMEM F12 HAM medium containing vectors or lipoplexes at 
the final concentrations given in the text and incubated for 2 h at 37°C. Then, the samples 
were diluted and plated on TSA (Fluka, Sigma-Aldrich, St. Louis, USA; S. aureus) or LB 
agar (Bioshop, Canada) plates (E. coli) and incubated for 12 h at 37°C. The CFU (Colony 
Forming Units; CFU/ml) was calculated and bacteria survival was shown as a percent of 
control. 
 
Red blood cell hemolysis assay  
A red blood cell (RBC) hemolytic activity of PTAI-based vectors and lipoplexes was tested 
with human RBCs suspended in PBS. RBCs derived from a healthy volunteer donor were 
purified in 3 centrifugation (1000 × g for 10 min at RT)/PBS re-suspension (2 × volume) 
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cycles and diluted in PBS (50-fold of original blood volume). Vectors and lipoplexes, 
suspended in F12 HAM medium, were added to RBC suspensions to achieve the 
concentrations given in the text, and incubated for 1 hr at 37°C. The samples were then 
centrifuged at 1000g for 10 min and the supernatants were transferred into a 96-well 
microtiter plate for haemoglobin release analysis. The relative haemoglobin concentration in 
supernatants was monitored with the Multiscan FC system (Thermo Scientific) by measuring 
the absorbance of the supernatant at 405 nm. Samples treated with 1% Triton X-100 were 
used as a positive (100%) control, whereas PBS/F12 HAM medium was used as a negative 
control.  
 
Statistical analysis  
Each parameter was calculated as the mean of three independent measurements +/- standard 
deviation (SD) or standard error of the mean (SEM) where indicated. In the time-lapse 
monitoring of movement of individual cells, the statistical significance between the speed of 
cell movement was determined by the Student's t-test. For the GJIC results the statistical 
significance was determined by the Dunnett’s test. No significant differences were found in 
both applied tests – Student's t-test (p>0.01), Dunnett’s test (p>0.05). 
 
Results 
 
Efficacy of PTAI-based lipofection is dependent on the length of the PTAI polyprenyl 
chain 
We have previously demonstrated that PTAI-7+DOPE-based lipoplexes show strong 
lipofecting activity which depends on the cationic lipid helper ratio [19]. Analyses performed 
in this study with the aid of confocal microscopy revealed the intranuclear localization of Cy-
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3-labeled plasmid DNA delivered with PTAI-7-based vectors in DU145 cells (Fig. 2A). 
These results prompted us to check if the length of the hydrophobic chain affects transfection 
efficiency of PTAI. GFP expression analyses demonstrated that all tested polyprenyl iodides 
with different lengths of polyprenyl chains (PTAI-7/8/11/15) were effective components of 
lipofecting mixtures (Fig. 2B). 
Application of 3µg/well AP-7+DOPE mixture at a molar ratio of 1.5:1, along with 
2µg/well of pEGFP-C1 plasmid yielded the optimal transfection efficiency of PTAI-7 (60.2 ± 
2.2%, Fig. 3A-C). Application of iodides with longer polyprenyl chains (especially PTAI-11 
and -15) yielded even higher transfection efficiencies, corresponding to those observed for 
the commercial lipofectant Lipofectamine 2000. Similar optimization performed for other 
PTAIs studies showed that the optimal PTAI:DOPE molar ratio for these compounds is 1.5:1 
or 1:1 for PTAI-8 or PTAI-11 and -15, respectively (Fig. 3D, Supplementary figures 2, 3, 4). 
We speculate that the estimated, relatively higher amount of helper lipid in lipoplexes may be 
necessary to compensate for lower lipid mixing (with cell or endosomal membrane lipids) 
and fusiogenic capacity of cationic lipids with longer hydrophobic chains as reported for 
other lipids [25].  
 Moreover, we observed that PTAI of higher lengths required an increased total lipid amount 
necessary for the optimal transfection efficiency (Fig. 3D, Supplementary figures 2, 3, 4).  
On the other hand, PTAI are monovalent lipids and their charge/mass ratio is strictly 
dependent on the length of the polyprenyl chain. Therefore, it seems possible that a larger 
amount of longer-chain PTAI is required to ensure the same pEGFP-C1 plasmid 
complexation capacity. This hypothesis was verified by carrying out a pEGFP-C1 plasmid 
gel retardation assay, which demonstrated that 15 µg of PTAI-7+DOPE (1.5:1) was sufficient 
for the optimal complexation of 2 µg of pEGFP-C1 (Fig. 3E). In contrast, even 20 µg of 
PTAI-11+DOPE was not enough to achieve such an effect. Furthermore, complete pEGFP-
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C1 plasmid complexation seemed unnecessary for optimal efficiency of transfection. In 
optimal conditions (3 µg of lipids for PTAI-7 and 7.5 µg for PTAI-11) as little as half of the 
pEGFP-C1 plasmid amount was complexed and protected from DNase degradation (Suppl. 
Fig. 5). This was illustrated by residual bands corresponding to free pEGFP-C1 plasmid upon 
electrophoretic analysis (Fig 3E), which on the other hand seemed to have no negative effect 
on transfection efficiency and was susceptible to DNAse treatment (Suppl. Fig. 5). 
Importantly, pEGFP-C1 plasmid binding properties of PTAI-based formulations are similar 
to those estimated for optimal efficiency of transfection of Lipofectamine 2000 (optimal 
transfection was achieved at 1 µl of Lipofectamine 2000, Fig 3E).  
 
Particle size and ζ potential as determinants of lipofecting activity of PTAI 
Our observations indicate that PTAI-based vectors are efficient plasmid DNA carriers and 
complete DNA complexation is not crucial for the efficiency of PTAI-based gene transfer. 
Therefore, we further concentrated on the determinants of PTAI-lipoplex efficiency. For 
instance, the size of lipoplexes is a parameter determining the efficiency of the endocytic 
pathway of lipoplex internalization. In our experiments, the sizes of the most effective PTAI 
lipoplexes were 200 – 300 nm, except for PTAI-15+DOPE vehicles which were 310 ± 22 nm 
and PTAI-15+DOPE +pEGFP-C1 lipoplexes which ranged between 426-485 nm (Fig. 4A). 
All of them are within the range of 200-500 nm that has been shown to enter cells via 
caveolae-mediated endocytosis [26]. There was also a small portion of much bigger (approx. 
5000 – 5500 nm) particles identified for all vehicles (1.6-3.2%) and PTAI-15+DOPE 
lipoplexes (4.1-5.1%). All of the lipoplexes maintained their initial size during 5h of 
experiment (Fig. 4A).  
Interestingly, when stored at 4°C, PTAI-7, -8 and 11 - based vectors were effective for at 
least 18 months of storage (data not shown). In contrast, PTAI-15 - based vectors lost their 
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lipofecting activity during storage. Their efficiency dropped to 15% and 2% of transfected 
cells after 1 month and 15 months post preparation, respectively, compared to freshly 
prepared lipofectant (data not shown). Interestingly, the loss of the lipofecting activity by 
vehicles during longer storage is characteristic only for PTAI-15+DOPE-based particles 
creating lipoplexes with a tendency for aggregation (Fig. 4A). 
Similarly to the size of lipoplexes, ζ potential has long been considered as a parameter 
correlated with the lipofecting capacity. Examination of ζ potential is an indirect estimation 
method of the particle surface charge. The positive charge of vehicles is supposed to enable 
interactions with negatively charged DNA. ζ potentials estimated for PTAI-based vehicles 
ranged between +21 and +31mV (Fig. 4B). Interestingly, a small but systematic decrease of 
zeta potential of vehicles and lipoplexes was observed along with the increasing length of the 
polyprenyl chain. This is probably connected with the charge/mass ratio of PTAI strictly 
dependent on the length of the chain. The positive charge of lipoplexes after DNA 
complexation is generally believed to be necessary to ensure the association of lipoplexes 
with cell membranes [27],[28]. However, PTAI-based lipoplexes were negatively charged 
(from -21 to -29 mV; Fig. 4). This somewhat surprising observation confirms that the positive 
charge of lipoplexes is not an absolute requirement for effective lipofection [29]. Moreover, 
negative ζ potential values of lipoplexes were reported to be beneficial for in vivo 
applications [30],[31]. All of these examinations consistently characterized PTAI-based DNA 
delivery vehicles as medium-sized, positively charged particles; their long-lasting DNA 
complexing capability makes them suitable for storage for at least 18 months (PTAI-7,8,11), 
while negatively charged lipoplexes work effectively for at least 5 h after preparation. 
For comparison, the previously described size of Lipofectamine 2000 liposomes was ~140-
500 nm  and lipoplexes ~150-600 nm [32],[33]. Lipofectamine 2000-based lipoplexes were 
reported to have a negative charge from -12 to -25 mV for different Lipofectamine2000/DNA 
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charge ratios, while Lipofectamine 2000 liposomes proved to be both positive +46.7 mV [33] 
and negative -4 mV [32]. Our results suggest that PTAI-based lipoplexes have similar 
characteristics to Lipofectamine 2000. This may be a promising prognostic factor as 
Lipofectamine2000 is one of the best commercially available lipofecting agents.    
 
Cell type-specific reactions of procaryotic and eukaryotic cells to PTAI-based 
lipofection  
Examination of the effect of PTAI-based vehicles and lipoplexes on procaryotic and 
eukaryotic cells may provide valuable information about their structure/function 
relationships. The expected outcome of the lipofection procedure is nucleic acid delivery 
without affecting target cell survival and physiology. To elucidate the effect of PTAI-
lipoplexes on target cells, we used the previously established approach based on the 
monitoring of basic traits of model prostate DU145 cells. Polyprenyl-based lipoplexes 
appeared to have no cytotoxic effect on DU145 cells (Fig. 5A). Instead, they exerted a 
significant effect on their proliferation (Fig. 5B) and morphology (Fig. 5D), which, however, 
was less pronounced than that of Lipofectamine 2000 (at least for PTAI-7). In order to reduce 
the unfavourable cytostatic effects of lipoplexes, their concentration was lowered to achieve 
efficient lipofection without any effect on cell proliferation (Fig. 5C). Thus, the conditions 
obtained during optimization of lipofection lead to formation of effectively acting lipoplexes 
which may successfully transfect cells even at lower, non-cytostatic concentration (Fig. 
5C,D). 
Moreover, it has long been suggested that EGFP expression affects cell physiology [34]. 
Therefore, experiments with an empty pcDNA3 plasmid were conducted and they revealed 
(Fig. 5C) that indeed cell proliferation is affected not only by the presence of lipids, but also 
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by EGFP expression itself. Thus an empty pcDNA3 plasmid was used in all subsequent 
experiments aimed at testing the impact of lipofection on the cell function. 
Non-cytostatic conditions (Fig. 5C,D) of PTAI-based lipofection were used for further 
analyses of their effects on DU145 cells (Fig. 6). As described above, our results 
demonstrated that even though lipofection exerted no cytotoxic effect on DU145 cells, it may 
affect other cellular processes (e.g. proliferation). However, analyses of lipoplex influence 
cell motility (pEGFP-C1 – Fig. 6A, pcDNA3 – data not shown) and gap junctional 
intercellular coupling (GJIC) (pcDNA3 – Fig. 6B,C) demonstrated that PTAI-based 
lipofection remained neutral to both of these traits. 
Although, eukaryotic cells were the focus of our attention, simplified cellular systems 
based on Gram-positive S. aureus, Gram-negative E. coli, and human red blood cells (RBCs) 
were also employed to comprehensively estimate PTAI-based carrier interactions with 
different cell types. Cationic DNA vehicles are believed to act analogously to naturally 
occurring peptide antibiotics due to their cationicity and amphipathicity, according to data 
proving their antibacterial activity [35]. Polyisoprenoids, polyprenyl-based vectors and 
lipoplexes were also tested in this context. 
All the vector formulations PTAI-7/8/11/15 + DOPE had strong antimicrobial activity 
against E. coli (Fig. 7A), while only PTAI-7+DOPE and PTAI-8+DOPE were significantly 
harmful for S. aureus (Fig. 7A). 
The difference may be due to the fact that Gram-negative E. coli has an outer membrane 
and exposes highly anionic lipids at its surface, which may be the target for positively-
charged polyprenyl-based vectors, while Gram-positive S. aureus has peptidoglycan on its 
surface, making lipid interaction more difficult. This activity was maintained for up to 17 
months after preparing a ready-to-use reagent (not shown). DOPE addition enhances PTAI 
activity against E. coli and reduces it against S. aureus (Fig. 7B). Since DOPE, used in 
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bacterial membrane-mimicking liposomes [36], strongly influences the membrane-disrupting 
activity of antibacterial agents [37], we hypothesize that it can facilitate interaction with the 
membrane of Gram-negative, but not Gram-positive bacterial cell surfaces. Neutralization of 
the positive charge by plasmid DNA also neutralizes antimicrobial properties (Fig. 7B). In 
the case of E. coli and newly prepared lipoplexes (Fig. 7B), this effect is incomplete. This 
indicates that not only the surface charge, but also the composition of interacting lipids plays 
a role in this process [37]. 
As our carriers are potentially good candidates for in vivo applications because of the 
negative charge of lipoplexes, experiments on the hemolytic activity of PTAI vectors and 
lipoplexes were conducted. In the case of sole cationic derivatives of polyprenols and the 
vehicles, the hemolytic activity was correlated with the length of the polyprenyl chain. 
Derivatives with shorter polyprenyl chains (PTAI-7, 8) ruptured RBC membranes more 
efficiently than their counterparts with longer ones (PTAI-11,15). A similar tendency was 
observed for the vehicles, while all the PTAI-based lipoplexes (PTAI-7, 8, 11 and 15) were 
neutral to RBCs (Tab. 1). Altogether these data confirm that the hemolytic activity (similarly 
to antimicrobial properties), depends on the positive charge of particles and is no longer 
present after complexation of plasmid DNA. 
 
 
Discussion 
The idea of constructing cationic vehicles built from linear isoprene polymers was 
prompted by reports on the effect of polyisoprenoid alcohols and their derivatives 
(phosphates) on the structure of lipid membranes [17],[38]. Since the pioneering work of 
Felgner et al. (1987) [39], finding an ideal cationic lipid and optimal formulation for 
lipofection has been regarded as a great challenge. Previously, we demonstrated that 
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lipoplexes prepared from a polyprenyl derivative of plant polyprenol (PTAI-7) and DOPE 
display a transfecting activity corresponding to that of Lipofectamine 2000 [19]. Here we 
present an optimized lipofecting mixture and show that the entire set of polyprenyl-based 
derivatives can be considered for creating new, effectively acting and stable lipofection 
reagents. Moreover, detailed elucidation of lipofection conditions established the 
determinants of DNA complexing and transfecting capability of PTAI-based lipoplexes.  
Whereas all tested PTAI-based compounds have high transfection efficiency, slight 
differences in optimal transfection conditions hinted towards the identification of features 
crucial for the transfecting capability. At the level of DNA complexing activity, the ability of 
vehicles to condense and protect DNA from degradation determines their efficacy. Positively-
charged vehicles readily interact with negatively charged nucleic acids and form lipoplexes 
most probably via electrostatic interaction when dispersed in an aqueous solution. This 
interaction is strictly connected with the positive charge of the applied lipid. Our observations 
show that the optimal amount of lipids used for transfection correlates with the increasing 
length of polyprenyl chain, confirming the relevance of this mechanism for PTAI-based 
vehicles, because a greater amount of monovalent PTAIs with longer polyprenyl chains is 
required to ensure the same positive charge and complex DNA as efficiently as short-chain 
polyprenols. Interestingly, free, non-complexed DNA probably remaining in the form of 
molecules less firmly bound to the surface of the lipoplex does not seem to have any 
unfavourable effect on transfection efficiency. Moreover, the hypothesis that it is required for 
the optimal efficiency and negative charge of lipoplexes can be taken into consideration. 
Our data also show that the DNA complexing capability of polyprenyl-based lipoplexes 
results in formation of middle-sized lipoplexes. The size measurement results show that 
polyprenols offer a great complexity. This is consistent with the literature. Studies on 
polyisoprenoids strongly suggest that these long-chain molecules when present in the lipid 
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bilayer possess a specific coiled conformation and consequently the length of the 
hydrocarbon chain is much shorter than the predicted sum of respective C-C bonds [40]–[43]. 
Conflicting data exist on the influence of the lipoplex size on transfection efficiency and the 
optimal size has not been clearly defined so far [44]. In our experiments, all of the lipoplexes 
were medium-sized (200-300 nm) and highly effective, despite suggestions that such particles 
may be limited by diffusion and trigger worse cellular trafficking than larger lipoplexes [45]. 
Larger particles, up to 400-500 nm, can be efficiently processed by internalization pathways 
[46] and targeted lipoplexes close to 300 nm can be efficiently used both in vitro and in vivo 
[47].  
Moreover, positively charged polyprenyl-based vectors meet the crucial requirement for 
interaction with the negatively charged phosphates on DNA: we demonstrated that efficient 
transfection was provided by negatively charged polyprenyl-based lipoplexes. This finding is 
somewhat surprising because positively-charged lipoplexes constitute the overwhelming 
majority of efficient non-viral vectors described in the literature and are generally considered 
more efficient [44]. The shift to a negative charge of lipid-based vehicles after DNA 
condensation was originally thought to ruin DNA protection and inhibit cell association and 
entry. Our results show that this is not an indispensable condition and negatively-charged 
lipoplexes still protect a sufficient amount of pDNA and successfully interact with cell 
membranes. This result finds confirmation in the literature [29],[33],[48]. However, some 
anionic lipoplexes are accompanied by Ca2+ ions [49]–[51] that are suggested to play a role 
in the lipoplex-cell membrane interactions. Anionic vehicles for nucleic acids are intensively 
developed [52]–[54]. Moreover, negatively charged lipoplexes can be useful for in vivo 
applications [30],[55] and are less toxic than positively charged ones [54],[56]. Our 
observations of the differences between the bacteriolytic and hemolytic activities of the 
vehicles and lipoplexes may support this notion. The addition of plasmid DNA neutralized 
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the positive charge and the antimicrobial properties of the lipoplexes. Thus, both the surface 
charge and the composition of interacting lipids is important for the activity of polyprenyl-
based vectors and lipoplexes. Anionic formulations were shown to be useful in lipofection of 
cells that are hard to transfect e.g. neurons [57], macrophages [58] and to exhibit high 
efficiency in the presence of serum and antibiotics [49],[57],[59]. Advantages of negatively 
charged particles in DNA and drug delivery results in different anionic formulations of 
different design – using anionic lipids [54], anionic polymers [60], anionic lipid bilayers 
coatings [61]. They are also useful in receptor-mediated transfection [62]. 
It was suggested that negatively charged lipoplexes enter the cells via caveolae [63] and a 
temperature-independent mechanism [29], and positively-charged lipoplexes can be the target 
of negatively charged serum components. This may lead to their opsonization and rapid 
clearance by the reticulo-endothelial system [31]. Thus, negatively charged lipoplexes may 
be the best solution for in vitro and in vivo lipofection. A strategy based on anionic 
complexes was also used for DNA delivery to protect the cargo from deactivation by 
polyanions present in tumor ascitic ﬂuid, such as hyaluronic acid (HA) [64]. Amphoteric 
liposomes (cationic at low pH and anionic at neutral pH) ensure DNA complexation but 
avoid blood interactions, thus facilitating well-tolerated targeted systemic oligonucleotide 
delivery to the sites of inflammation [65]. Efficiency of polyprenyl-based lipoplexes as 
delivery vectors in vitro also makes them potentially effective vectors for in vivo applications. 
Although not cytotoxic, polyprenyl-based lipoplexes, when applied at higher lipid 
concentrations, exerted an inhibitory effect on DU145 proliferation and morphology. 
Nevertheless, this unfavourable effect was lower (for PTAI-7+DOPE lipoplexes) than for 
commercially available Lipofectamine 2000 and could easily be eliminated by lowering their 
concentration without affecting the efficiency. This cytostatic effect may, however, be the 
result of GFP expression, since an empty pcDNA3 plasmid did not exert this effect on 
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DU145. Moreover, PTAI-based lipoplexes had no effect on cell motility, GJIC (Fig. 6) and 
did not disrupt human RBC membranes (Tab. 1) which is considered as highly beneficial for 
in vivo use. While the lack of cytotoxicity on eukaryotic cells is required to find an ideal 
DNA vector, its opposite impact on bacteria may be beneficial. Polyprenyl-based vectors 
meet both of these criteria. All the vector formulations PTAI-7, -8, -11 or -15 + DOPE have 
antibacterial activity at concentrations not affecting DU145 cell survival. We have also 
shown that PTAI-7, -8 or -11+DOPE vectors are not only stable and effective, but also 
maintain their antimicrobial properties (PTAI-7+DOPE) up to 17 months after preparing a 
ready-to-use reagent. This provides an excellent basis for safe and easy storage. 
 
Conclusions 
Although it is generally considered that lipoplexes bearing positive zeta potential are more 
efficient as lipofectants, our data indicate that this is not always the case. In our experiments, 
the positive charge is unnecessary for interaction of lipoplexes with the membranes of 
eukaryotic cells. We demonstrate that the negatively charged polyprenyl-based lipoplexes are 
efficient plasmid DNA delivery vectors. Moreover, they exhibit many advantages such as 
effective transfection without cytotoxicity and impact on eukaryotic cell proliferation, 
motility and GJIC as well as antimicrobial properties and no hemolytic activity against 
human RBCs. Taken together, the PTAI-based lipoplexes are good candidates for delivery of 
genetic material to eukaryotic cells.  
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TABLES 
 
Table 1. No hemolytic activity of PTAI-based lipoplexes against human RBCs. Each 
value represents the mean ± S.D. (n = 3), n.a. – not applicable. 
 
 PTAI-7 PTAI-8 PTAI-11 PTAI-15 Lipof. 2000 
PTAI µg % µg % µg % µg % µl % 
 
 
PTAI 
 
2.5 
3.0 
4.0 
5.0 
 
22.2 ± 0.9 
23.2 ± 0.6 
32.7 ± 0.7 
40.9 ± 1.6 
 
3.0 
3.5 
4.5 
 
30.9 ± 0.5 
37.0 ± 0.7 
42.4 ± 1.1 
 
4.0 
6.0 
7.5 
 
10.1 ± 0.5 
17.1 ± 0.2 
40.1 ± 1.8 
 
5.0 
8.5 
10.0 
12.5 
 
  7.9 ± 0.2 
14.3 ± 0.8 
20.5 ± 0.6 
25.5 ± 0.2 
 
n.a. 
 
n.a. 
 
 
PTAI+ 
DOPE 
 
2.5 
3.0 
4.0 
5.0 
 
10.5 ± 0.3 
16.4 ± 0.7 
19.4 ± 0.6 
44.2 ± 1.4 
 
3.0 
3.5 
4.5 
 
23.2 ± 0.7 
31.4 ± 1.8 
42.7 ± 0.6 
 
4.0 
6.0 
7.5 
 
4.1 ± 0.3 
5.2 ± 0.4 
6.8 ± 0.2 
 
5.0 
8.5 
10.0 
12.5 
 
1.3 ± 0.1 
1.7 ± 0.1 
1.6 ± 0.1 
1.9 ± 0.2 
 
1.0 
1.5 
3.0 
5.0 
 
3.6 ± 0.1 
3.6 ± 0.1 
6.9 ± 0.9 
8.2 ± 0.7 
 
PTAI+ 
DOPE+ 
pDNA 
 
2.5 
3.0 
4.0 
5.0 
 
1.7 ± 0.1 
2.1 ± 0.1 
2.5 ± 0.1 
5.3 ± 0.4 
 
3.0 
3.5 
4.5 
 
2.0 ± 0.2 
2.2 ± 0.1 
2.4 ± 0.1 
 
4.0 
6.0 
7.5 
 
3.2 ± 0.1 
3.2 ± 0.0 
5.7 ± 0.2 
 
5.0 
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FIGURES 
 
 
 
Figure 1. Structure of trimethylpolyprenylammonium iodides (PTAI), n=7/8/11/15 used in 
the study. 
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Figure 2. Efficient DNA transfer into DU145 cells. A - Intranuclear localization of Cy-3-
labeled pDNA (red) delivered with PTAI-7+DOPE 4 hours after transfection. Hoechst 33342-
labeled nuclei - blue. Results illustrated in XY, XZ, and YZ projections of cells. Arrows 
indicate lipoplexes shown in XY (white), XZ and YZ (grey) projections. PTAI-7:DOPE 
molar ratio – 1.5:1, 2 µg Cy-3-labeled pDNA/well (24-well plate), 3 µg of PTAI-
7+DOPE/well, charge ratio 1:2.3. B - DU145 cells efficiently transfected with PTAI-
7+DOPE (1.5:1 M/M, 3 µg/well, charge ratio 1:2.3), PTAI-8+DOPE (1.5:1 M/M, 4.5 
µg/well, charge ratio 1:1.6), PTAI-11+DOPE (1:1 M/M, 7.5 µg/well, charge ratio 1:1.3), 
PTAI-15+DOPE (1:1 M/M, 8.5 µg/well, charge ratio 1:1.4), 2 µg of pEGFP-C1 plasmid/well. 
Phase contrast (phase) and epifluorescence microscopy with FITC filter (GFP) images. 
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Figure 3. Optimization of PTAI-based lipofection with pEGFP-C1 plasmid into DU145 cells 
and DNA complexing ability of PTAI. A – efficiency of transfection for different PTAI-
7:DOPE molar ratio; 0.25µg pEGFP-C1/well (24-well plate), 1µg PTAI-7+DOPE/well, B - 
efficiency of transfection for different PTAI-7+DOPE concentration; PTAI-7:DOPE molar 
ratio – 1.5:1, 1.5µg pEGFP-C1/well, C – efficiency of transfection for different DNA 
concentration; 3µg PTAI-7+DOPE/well, PTAI-7:DOPE molar ratio – 1.5:1, control – 
Lipofectamine 2000 (1µl+2µg pEFP-C1), D – optimal transfection conditions for 
PTAI+DOPE. E - Gel electrophoresis of PTAI-7+DOPE+pEGFP-C1 lipoplexes (PTAI-
7+DOPE [µg] / 2 µg of pEGFP-C1), PTAI-11+DOPE+pEGFP-C1 (PTAI-11+DOPE [µg] / 2 
µg of pDNA) and Lipofectamine 2000+pEGFP-C1 lipoplexes (Lipofectamine 2000 [µl] / 2 
µg pDNA). Charge ratio (PTAI
+
:DNA
-
) shown above the bars (A, B, C) and below the photo 
(E). Each value represents the mean ± S.D. (n = 3-7). 
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Figure 4. Size and zeta potential of vehicles and lipoplexes. Measurements show the medium 
size (A) and negative charge (B) of lipoplexes. PDI - polydispersity index. Vehicle and 
lipoplex characterization shown in fig. 3D. Each value represents the mean ± S.D. (n = 5 [A], 
n = 16 [B]). 
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Figure 5. PTAI cytotoxicity and its effects on DU145 cell proliferation and morphology. 
FDA and EtBr assays revealed no cytotoxicity on DU145 cells (A) and cell counting showed 
a negative impact on cell proliferation (C) and morphology (D) that was eliminated by 
lowering the concentration of lipoplexes (C – arrows indicate optimal concentrations of 
PTAI-based lipoplexes not affecting cell proliferation). Transfection with non-coding 
pcDNA3 plasmid showed that EGFP expression could be partially the reason of the effect on 
proliferation (C). A, B - PTAI-7+DOPE (1.5:1 M/M, 3 µg of lipids/well [24-well plate], 
charge ratio 1:2.3), PTAI-8+DOPE (1.5:1 M/M, 4.5 µg of lipids/well, charge ratio 1:1.6), 
PTAI-11+DOPE (1:1 M/M, 7.5 µg of lipids/well, charge ratio 1:1.3), PTAI-15+DOPE (1:1 
M/M, 8.5 µg of lipids/well, charge ratio 1:1.4), Lipofectamine 2000 (1µl), 2 µg pEGFP-
C1/well. C – X-axis – amount of lipids in µg. Decreasing the Lipofectamine 2000+pEGFP-
C1 lipoplex amount to 0.75µl/well resulted in a significant loss of transfection efficiency, 
thus the concentration of Lipofectamine 2000 was increased in the step of lipoplex 
preparation (1.5µl/2µg pEGFP-C1) and lowered when adding to cells resulting in non-
cytostatic, efficient lipofection. Each value represents the mean ± S.D. (n = 3). 
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Figure 6. Effects of PTAI on DU145 cell migration and GJIC. Time-lapse monitoring of 
movement of individual cells 24 h after transfection with pEGFP-C1 plasmid showed no 
effects of PTAI-based lipofection on DU145 cell migration. Trajectories of cells presented in 
the form of a circular diagram drawn with the initial point of each trajectory placed at the 
origin of the plot. V - the speed of cell movement (μm/h). GJIC assay results 24 hours after 
transfection with PTAI-based lipoplexes with pcDNA3 plasmid revealed no impact on GJIC. 
Calcein transfer – green, donor cells – red. PTAI-7+DOPE – 2.5 µg/well (24-well plate), 
charge ratio 1:2.3, PTAI-8+DOPE – 3 µg/well, charge ratio 1:1.6, PTAI-11+DOPE – 4 
µg/well, charge ratio 1:1.3, PTAI-15+DOPE – 5 µg/well, charge ratio 1:1.4, pcDNA3 
plasmid used in all experiments. A - Each value represents the mean ± SEM (n = 50). The 
statistical significance between samples was determined by the Student's t-test (p<0.01). B - 
Each value represents the mean ± S.D. (n = 35). The statistical significance was determined 
by the Dunnett’s test (p<0.05). No statistically significant differences were found. 
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Figure 7. Antimicrobial activity of PTAI. PTAI and PTAI+DOPE showed antimicrobial 
activity against E. coli and S. aureus (A, B). Plasmid DNA addition neutralizes antimicrobial 
properties (B). Lipoplex concentrations represented as the amount of PTAI-7+DOPE – 2.5 
µg/well (24-well plate), PTAI-8+DOPE – 3 µg/well, PTAI-11+DOPE – 4 µg/well, PTAI-
15+DOPE – 5 µg/well. Each value represents the mean ± SEM (n=12). The statistical 
significance versus control was determined by Kruskal-Wallis test (p<0.05), * - p < 0.05, ** 
< 0.01, *** < 0.001. 
